UFT	0	3	B-Drug_or_compound
and	4	7	O
its	8	11	O
metabolites	12	23	O
inhibit	24	31	O
the	32	35	O
angiogenesis	36	48	O
induced	49	56	O
by	57	59	O
murine	60	66	B-Organism
renal	67	72	B-Pathological_formation
cell	73	77	I-Pathological_formation
carcinoma	78	87	I-Pathological_formation
,	87	88	O
as	89	91	O
determined	92	102	O
by	103	105	O
a	106	107	O
dorsal	108	114	O
air	115	118	O
sac	119	122	O
assay	123	128	O
in	129	131	O
mice	132	136	B-Organism
.	136	137	O

UFT	139	142	B-Drug_or_compound
,	142	143	O
an	144	146	O
anticancer	147	157	O
agent	158	163	O
that	164	168	O
is	169	171	O
composed	172	180	O
of	181	183	O
tegafur	184	191	B-Drug_or_compound
(	192	193	O
FT	193	195	B-Drug_or_compound
)	195	196	O
and	197	200	O
uracil	201	207	B-Drug_or_compound
at	208	210	O
a	211	212	O
molar	213	218	O
ratio	219	224	O
of	225	227	O
1	228	229	O
:	229	230	O
4	230	231	O
,	231	232	O
is	233	235	O
widely	236	242	O
used	243	247	O
in	248	250	O
clinical	251	259	O
practice	260	268	O
in	269	271	O
Japan	272	277	O
to	278	280	O
treat	281	286	O
cancer	287	293	B-Pathological_formation
patients	294	302	B-Organism
requiring	303	312	O
a	313	314	O
long	315	319	O
-	319	320	O
term	320	324	O
chemotherapy	325	337	O
,	337	338	O
and	339	342	O
it	343	345	O
is	346	348	O
associated	349	359	O
with	360	364	O
few	365	368	O
side	369	373	O
effects	374	381	O
,	381	382	O
if	383	385	O
any	386	389	O
.	389	390	O

In	391	393	O
this	394	398	O
study	399	404	O
,	404	405	O
we	406	408	O
have	409	413	O
evaluated	414	423	O
the	424	427	O
inhibitory	428	438	O
effect	439	445	O
of	446	448	O
UFT	449	452	B-Drug_or_compound
against	453	460	O
RENCA	461	466	B-Cell
cell	467	471	I-Cell
-	471	472	O
induced	472	479	O
angiogenesis	480	492	O
by	493	495	O
a	496	497	O
dorsal	498	504	O
air	505	508	O
sac	509	512	O
assay	513	518	O
.	518	519	O

Marked	520	526	O
angiogenesis	527	539	O
is	540	542	O
induced	543	550	O
by	551	553	O
implantation	554	566	O
of	567	569	O
a	570	571	O
chamber	572	579	O
containing	580	590	O
RENCA	591	596	B-Cell
cells	597	602	I-Cell
into	603	607	O
mice	608	612	B-Organism
.	612	613	O

In	614	616	O
this	617	621	O
model	622	627	O
,	627	628	O
UFT	629	632	B-Drug_or_compound
showed	633	639	O
a	640	641	O
strong	642	648	O
angiogenesis	649	661	O
-	661	662	O
inhibitory	662	672	O
effect	673	679	O
,	679	680	O
whereas	681	688	O
5	689	690	B-Drug_or_compound
-	690	691	I-Drug_or_compound
fluorouracil	691	703	I-Drug_or_compound
(	704	705	O
5	705	706	B-Drug_or_compound
-	706	707	I-Drug_or_compound
FU	707	709	I-Drug_or_compound
)	709	710	O
and	711	714	O
doxifluridine	715	728	B-Drug_or_compound
were	729	733	O
less	734	738	O
effective	739	748	O
.	748	749	O

Additional	750	760	O
experiments	761	772	O
revealed	773	781	O
FT	782	784	B-Drug_or_compound
to	785	787	O
be	788	790	O
effective	791	800	O
component	801	810	O
of	811	813	O
UFT	814	817	B-Drug_or_compound
;	817	818	O
uracil	819	825	B-Drug_or_compound
remained	826	834	O
ineffective	835	846	O
in	847	849	O
the	850	853	O
inhibition	854	864	O
of	865	867	O
angiogenesis	868	880	O
.	880	881	O

Moreover	882	890	O
,	890	891	O
we	892	894	O
have	895	899	O
found	900	905	O
that	906	910	O
gamma	911	916	B-Drug_or_compound
-	916	917	I-Drug_or_compound
hydroxybutyric	917	931	I-Drug_or_compound
acid	932	936	I-Drug_or_compound
and	937	940	O
gamma	941	946	B-Drug_or_compound
-	946	947	I-Drug_or_compound
butyrolactone	947	960	I-Drug_or_compound
,	960	961	O
the	962	965	O
metabolites	966	977	O
of	978	980	O
FT	981	983	B-Drug_or_compound
,	983	984	O
possess	985	992	O
a	993	994	O
potent	995	1001	O
angiogenesis	1002	1014	O
inhibitory	1015	1025	O
effect	1026	1032	O
that	1033	1037	O
is	1038	1040	O
amplified	1041	1050	O
when	1051	1055	O
the	1056	1059	O
compounds	1060	1069	O
are	1070	1073	O
administered	1074	1086	O
by	1087	1089	O
a	1090	1091	O
continuous	1092	1102	O
infusion	1103	1111	O
.	1111	1112	O

This	1113	1117	O
may	1118	1121	O
reflect	1122	1129	O
a	1130	1131	O
transition	1132	1142	O
in	1143	1145	O
blood	1146	1151	B-Organism_substance
concentration	1152	1165	O
of	1166	1168	O
each	1169	1173	O
metabolite	1174	1184	O
resulting	1185	1194	O
from	1195	1199	O
the	1200	1203	O
administration	1204	1218	O
of	1219	1221	O
UFT	1222	1225	B-Drug_or_compound
.	1225	1226	O

Similar	1227	1234	O
results	1235	1242	O
were	1243	1247	O
also	1248	1252	O
obtained	1253	1261	O
with	1262	1266	O
respect	1267	1274	O
to	1275	1277	O
5	1278	1279	B-Drug_or_compound
-	1279	1280	I-Drug_or_compound
FU	1280	1282	I-Drug_or_compound
.	1282	1283	O

It	1284	1286	O
was	1287	1290	O
suggested	1291	1300	O
that	1301	1305	O
UFT	1306	1309	B-Drug_or_compound
has	1310	1313	O
a	1314	1315	O
stronger	1316	1324	O
angiogenesis	1325	1337	O
-	1337	1338	O
inhibitory	1338	1348	O
effect	1349	1355	O
than	1356	1360	O
did	1361	1364	O
other	1365	1370	O
fluorinated	1371	1382	B-Drug_or_compound
pyrimidines	1383	1394	I-Drug_or_compound
,	1394	1395	O
partly	1396	1402	O
due	1403	1406	O
to	1407	1409	O
its	1410	1413	O
pharmacokinetic	1414	1429	O
properties	1430	1440	O
characterized	1441	1454	O
by	1455	1457	O
maintaining	1458	1469	O
of	1470	1472	O
higher	1473	1479	O
and	1480	1483	O
long	1484	1488	O
-	1488	1489	O
lasting	1489	1496	O
blood	1497	1502	B-Organism_substance
levels	1503	1509	O
of	1510	1512	O
5	1513	1514	B-Drug_or_compound
-	1514	1515	I-Drug_or_compound
FU	1515	1517	I-Drug_or_compound
and	1518	1521	O
partly	1522	1528	O
due	1529	1532	O
the	1533	1536	O
inhibitory	1537	1547	O
effects	1548	1555	O
derived	1556	1563	O
from	1564	1568	O
gamma	1569	1574	B-Drug_or_compound
-	1574	1575	I-Drug_or_compound
hydroxybutyric	1575	1589	I-Drug_or_compound
acid	1590	1594	I-Drug_or_compound
and	1595	1598	O
gamma	1599	1604	B-Drug_or_compound
-	1604	1605	I-Drug_or_compound
butyrolactone	1605	1618	I-Drug_or_compound
,	1618	1619	O
UFT	1620	1623	B-Drug_or_compound
-	1623	1624	O
specific	1624	1632	O
metabolites	1633	1644	O
.	1644	1645	O

